ProTECT III, the results of which were published alongside those of the SYNAPSE-trial in the December 25 2014 issue of NEJM, demonstrates no patient-important advantage conferred by the administration of progesterone (albeit very early in this particular study) to TBI patients.

“This clinical trial did not show a benefit of progesterone over placebo in the improvement of outcomes in patients with acute TBI”

Very Early Administration of Progesterone for Acute Traumatic Brain Injury. Wright et al. NEJM 2014. Read the article here.